PharmaShots | Incisive News in 3 Shots

Subscribe Now

Kashiv Biosciences

Kashiv BioSciences Reports the First Patient Enrolment of ADL018 (biosimilar, omalizumab) in the P-III Clinical Study for Chronic Spontaneous Urticaria

Kashiv BioSciences Reports the First Patient Enrolment of ADL018 (biosimilar, omalizumab) in the P-III Clinical Study for Chronic...

October 3, 2023

Kashiv Biosciences Reports P-I Clinical Study Results of ADL018 (biosimilar, omalizumab)

Kashiv Biosciences Reports P-I Clinical Study Results of ADL018 (biosimilar, omalizumab)

July 5, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us